GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Loans Receivable

Coherus BioSciences (FRA:8C5) Loans Receivable : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Loans Receivable?

Coherus BioSciences's Loans Receivable for the quarter that ended in Mar. 2024 was €0.0 Mil.


Coherus BioSciences Loans Receivable Historical Data

The historical data trend for Coherus BioSciences's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Loans Receivable Chart

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Coherus BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Coherus BioSciences Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Coherus BioSciences Loans Receivable Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (FRA:8C5) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines